Naing Lin Shan, MBBS, PhD, MS
Postdoctoral AssociateAbout
Research
Publications
Featured Publications
Intratumour heterogeneity, from hypothesis to the clinic
Shan NL, Kahn A, Pusztai L. Intratumour heterogeneity, from hypothesis to the clinic. British Journal Of Cancer 2022, 128: 459-460. PMID: 36216884, PMCID: PMC9938204, DOI: 10.1038/s41416-022-02008-w.Commentaries, Editorials and LettersComprehensive Analysis of Metabolic Isozyme Targets in Cancer
Marczyk M, Gunasekharan V, Casadevall D, Qing T, Foldi J, Sehgal R, Shan NL, Blenman KRM, O'Meara TA, Umlauf S, Surovtseva YV, Muthusamy V, Rinehart J, Perry RJ, Kibbey R, Hatzis C, Pusztai L. Comprehensive Analysis of Metabolic Isozyme Targets in Cancer. Cancer Research 2022, 82: 1698-1711. PMID: 35247885, PMCID: PMC10883296, DOI: 10.1158/0008-5472.can-21-3983.Peer-Reviewed Original ResearchConceptsPotential therapeutic targetAcetyl-CoA carboxylase 1Therapeutic targetCancer typesCell linesBreast cancer viabilityPatient-derived xenograftsNovel metabolic targetsCorresponding cell linesExpression patternsDrug treatmentMatching normal tissuesRelated commentaryTumor growthMalignant transformationSmall molecule inhibitionCancer viabilityCancer Cell Line EncyclopediaNormal tissuesMetabolic vulnerabilitiesCarboxylase 1Anticancer therapyCellular changesCell proliferationMetabolic reprogrammingMolecular differences between younger versus older ER-positive and HER2-negative breast cancers
Qing T, Karn T, Rozenblit M, Foldi J, Marczyk M, Shan N, Blenman K, Holtrich U, Kalinsky K, Meric-Bernstam F, Pusztai L. Molecular differences between younger versus older ER-positive and HER2-negative breast cancers. Npj Breast Cancer 2022, 8: 119. PMID: 36344517, PMCID: PMC9640562, DOI: 10.1038/s41523-022-00492-0.Peer-Reviewed Original ResearchBreast cancerYounger patientsHER2-negative breast cancerNode-positive breast cancerNode-negative diseaseSame clinical featuresHigh mutation burdenLower mRNA expressionAdjuvant chemotherapyMicroarray cohortTAILORx trialOvarian suppressionOlder patientsPatient ageClinical featuresProliferation-related gene expressionScore 0Mutation burdenCopy number gainsOlder womenGATA3 mutationsAge groupsGene signatureMRNA expressionChemotherapyAnalysis of the Transcriptome: Regulation of Cancer Stemness in Breast Ductal Carcinoma In Situ by Vitamin D Compounds
Shan N, Minden A, Furmanski P, Bak M, Cai L, Wernyj R, Sargsyan D, Cheng D, Wu R, Kuo H, Li S, Fang M, Maehr H, Kong A, Suh N. Analysis of the Transcriptome: Regulation of Cancer Stemness in Breast Ductal Carcinoma In Situ by Vitamin D Compounds. Cancer Prevention Research 2020, 13: 673-686. PMID: 32467291, PMCID: PMC7415686, DOI: 10.1158/1940-6207.capr-19-0566.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingCell Line, TumorCell ProliferationDatasets as TopicDisease ProgressionDNA MethylationDown-RegulationEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHumansNeoplasm InvasivenessNeoplastic Stem CellsRNA-SeqSignal TransductionUp-RegulationVitamin DConceptsCancer stem-like cellsStem-like cellsInvasive ductal carcinomaVitamin D compoundsNext-generation RNA sequencingCancer stem cell-like populationsGlobal transcriptomic analysisStem cell-like populationIngenuity Pathway AnalysisDuctal carcinomaCell-like populationD compoundsTranscriptomic analysisVitamin DGene methylation statusRNA sequencingEpithelial-mesenchymal transitionGlobal profilingPathway genesBreast cancer stem-like cellsCanonical pathwaysNegative regulatorUpstream regulatorPathway analysisNew breast cancer diagnosesVitamin D compounds inhibit cancer stem-like cells and induce differentiation in triple negative breast cancer
Shan N, Wahler J, Lee H, Bak M, Gupta S, Maehr H, Suh N. Vitamin D compounds inhibit cancer stem-like cells and induce differentiation in triple negative breast cancer. The Journal Of Steroid Biochemistry And Molecular Biology 2016, 173: 122-129. PMID: 27923595, PMCID: PMC5459680, DOI: 10.1016/j.jsbmb.2016.12.001.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerVitamin D compoundsCancer stem-like cellsNegative breast cancerBreast cancerStem-like cellsVitamin DCancer stem cellsD compoundsGemini vitamin D analog BXL0124Early breast cancer preventionBreast cancer stem-like cellsBreast cancer stem cell maintenanceBasal-like breast cancerMammosphere cultureBreast cancer preventionCancer cellsCancer stem cell markersPotential preventive agentBreast cancer subtypesBreast cancer cell linesTriple-negative breast cancer cell linesSmooth muscle actinBreast cancer cellsStem-like propertiesBreast cancer stem cells: A review of their characteristics and the agents that affect them
Shan N, Shin Y, Yang G, Furmanski P, Suh N. Breast cancer stem cells: A review of their characteristics and the agents that affect them. Molecular Carcinogenesis 2021, 60: 73-100. PMID: 33428807, PMCID: PMC7855917, DOI: 10.1002/mc.23277.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsBreast cancer stem cellsCancer stem cellsBreast cancerCell surface markersCombination therapyTherapeutic effectNew tumorsEffective treatmentXenografted miceCancer developmentSurface markersSerial transplantationCancerPotential agentFurther studiesTranscription factorsTumorsStem cellsBiological effectsKPT-9274, an Inhibitor of PAK4 and NAMPT, Leads to Downregulation of mTORC2 in Triple Negative Breast Cancer Cells
Cordover E, Wei J, Patel C, Shan N, Gionco J, Sargsyan D, Wu R, Cai L, Kong A, Jacinto E, Minden A. KPT-9274, an Inhibitor of PAK4 and NAMPT, Leads to Downregulation of mTORC2 in Triple Negative Breast Cancer Cells. Chemical Research In Toxicology 2019, 33: 482-491. PMID: 31876149, PMCID: PMC9316853, DOI: 10.1021/acs.chemrestox.9b00376.Peer-Reviewed Original ResearchConceptsCell growthSerine/threonine kinase mTORNicotinamide phosphoribosyltransferaseBreast cancer cellsTNBC cellsRegulation of RictorPak4 protein kinaseCancer cellsInhibition of PAK4Triple-negative breast cancerTriple-negative breast cancer cellsMTORC2 signalingKinase mTORProtein kinaseRNA sequencingTNBC cell growthNegative breast cancer cellsCell metabolismRictorPAK4Overexpressing cellsSpecific inhibitorDruggable targetsMTOR pathwayInhibits growthEvaluation of large language models as a diagnostic aid for complex medical cases
Ríos-Hoyo A, Shan N, Li A, Pearson A, Pusztai L, Howard F. Evaluation of large language models as a diagnostic aid for complex medical cases. Frontiers In Medicine 2024, 11: 1380148. PMID: 38966538, PMCID: PMC11222590, DOI: 10.3389/fmed.2024.1380148.Peer-Reviewed Original ResearchClinical casesLanguage modelHospital case recordsConsecutive clinical casesDifferential diagnosis listComplex clinical casesDifferential diagnosisDiagnostic considerationsCase discussionDiagnostic aidCase recordsDiagnosisComplex medical casesDiagnosis listDifferential listMedical specialtiesMedical professionalsDiseaseIncidence
2024
Circulating tumor DNA fraction predicts residual cancer burden post-neoadjuvant chemotherapy in triple negative breast cancer
Shan N, Gould B, Wang X, Bonora G, Blenman K, Foldi J, Campos G, Walsh M, Du P, Pusztai L. Circulating tumor DNA fraction predicts residual cancer burden post-neoadjuvant chemotherapy in triple negative breast cancer. The Journal Of Liquid Biopsy 2024, 6: 100168. DOI: 10.1016/j.jlb.2024.100168.Peer-Reviewed Original ResearchTriple negative breast cancerResidual cancer burdenCirculating tumor DNANegative breast cancerPathological responsePost-NACBreast cancerPlasma circulating tumor DNATriple negative breast cancer patientsResidual cancer burden scoreCirculating tumour DNA fractionPost-neoadjuvant chemotherapyPre-NAC samplesWeekly nab-paclitaxelTumor DNA methylation profilesTumor DNA fractionHot spot mutationsYouden's J statisticNab-paclitaxelPre-NACTumor variantsTumor DNATumor fractionClinical trialsDNA methylation profilesPhosphoenolpyruvate carboxykinase-2 (PCK2) is a therapeutic target in triple-negative breast cancer
Gunasekharan V, Lin H, Marczyk M, Rios-Hoyo A, Campos G, Shan N, Ahmed M, Umlauf S, Gareiss P, Raaisa R, Williams R, Cardone R, Siebel S, Kibbey R, Surovtseva Y, Pusztai L. Phosphoenolpyruvate carboxykinase-2 (PCK2) is a therapeutic target in triple-negative breast cancer. Breast Cancer Research And Treatment 2024, 208: 657-671. PMID: 39177932, DOI: 10.1007/s10549-024-07462-z.Peer-Reviewed Original ResearchMetabolic fluxTriple-negative breast cancerReduced metabolic fluxMDA-MB-231 cellsCell growth in vitroEnzyme assays in vitroMDA-MB-231Potential small molecule inhibitorsPyruvate carboxylaseGrowth in vitroSmall molecule inhibitorsIn silico screeningEnzyme assaysAssay in vitroEnzymatic assayCell lines in vitroEnzyme activityGrowth inhibitory activityBT-549Breast cancerIn vitro screeningBreast cell lines in vitroPhosphoenolpyruvateSignificant growth inhibitory activityLines in vitro